All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
Long Non-Coding RNAs (IncRNAs) are a class of RNA molecules that are longer than 200 nucleotides with no protein coding potential. IncRNAs has been shown to contribute to the initiation, maintenance, and development of Acute Myeloid Leukemia (AML).1 However, the prognostic importance of IncRNAs in the clinical outcomes of AML patients has not been extensively explored.
Dimitrios Papaioannou from The Ohio State University, Comprehensive Cancer Center, Columbus, USA, and colleagues investigated the prognostic and biological significance of IncRNAs in Cytogenetically Normal AML (CN-AML). The results of the study were published ahead of print in Haematologica on 4th May 2017.
In this study, whole transcriptome sequencing was used to characterize the IncRNAs profiles of 377 pre-treatment bone marrow or blood samples from young adults patients with de novo CN-AML (17–59 years) who received intensive induction therapy on the Cancer and Leukemia Group B (CALCGB)/Alliance for Clinical Trials in Oncology trials. Patients samples were split into two cohorts, training (n = 263) and validation (n = 114).
In summary, “IncRNA provides a meaningful prognostic information in young adults with CN-AML”. Furthermore, “expression of prognostic IncRNAs may regulate distinct molecular pathways in CN-AML”.
Subscribe to get the best content related to AML delivered to your inbox